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compression fractures in Spain. METHODS: Two alternative
models will be introduced here. One standard contingent valua-
tion model (CV), where mean values for willingness to pay
(WTP) for the treatment with BKP are obtained through a survey
including patients with primary osteoporosis. A new quality of
life adjusted wages model (QAW) is also introduced here. The
main assumption of this model is that a disease acts on individu-
als as a tax, where wages are deﬂected here by a quality of life
index (EuroQol 5-D) in the same way as a proportional income
tax. The burden of disease is given by this model in terms of an
equivalent variation or welfare changes in monetary terms. The
model avoids different kind of biases introduced in many times
by the CV approach and is a faster and more rigorous tool to ﬁnd
welfare changes determined by diseases and their medical treat-
ments. RESULTS: A sample of 168 individuals who had been
asked about their WTP for BKP was used to develop the CV
model. A mean value for WTP of €3909 is revealed by the
sample. A sample of 300 patients 21 years of age or older and
both genders coming from a clinical trial designed by Kyphon,
was used to develop QAW model, here is that BKP determines in
the ﬁrst month a yearly welfare gain of €2665, increased to
€3311 after 12 months. CONCLUSIONS: The results using CV
models and QAW model are similar in the ﬁrst year of life. It can
be explained through a temporal downward bias introduced by
WTP responses that means that a patient doesn’t include in his
personal WTP an estimation of his life expectancy.
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OBJECTIVES: Evidence-based guidelines recommend treatment
for postmenopausal women with osteoporosis to prevent frac-
tures. The study aims at determining since when this was known
and whether the utilization of bisphosphonates in Germany from
this point onward was adequate and to what extent health gains
might have been foregone due to a limited use of bisphosphonates.
METHODS: To determine since when the beneﬁcial effect (pre-
vention of fractures) was known, cumulative meta-analyses of
randomized controlled trials derived from systematic reviews
were conducted. The evidence-base was considered as established,
when a signiﬁcant (5%-level) reduction of fractures was observed
in trial populations combined inmeta-analysis compared to thera-
pies without bisphosphonates. Utilization ﬁgures for bisphospho-
nates and epidemiological estimates where taken from published
sources. RESULTS: The hip/femur fracture risk was signiﬁcantly
lower if treatment included bisphosphonates compared to treat-
ment without bisphosphonates (RR 0.62; 95%-CI 0.40–0.97 / RR
0.45; 95%-CI 0.23–0.90). In principal, this was known since
1995/1996. Utilization of bisphosphonates in 1996 was sufﬁcient
for the continuous treatment of about 8,200 patients (440,000
patients in 2006). About 1.6 to 1.9million patients annuallymight
have beneﬁtted from treatment. About 22,800 fractures might
thus have been avoided, had all patients with potential beneﬁt
continuously received bisphosphonates since 1996/1997. CON-
CLUSIONS: The delay in the wider use of bisphosphonates for
osteoporosis treatment has resulted in a considerable loss of
potential health gains in terms of avoided fractures. An arguable
lack of evidence for the expected beneﬁt from bisphosphonate
therapy does not sufﬁciently explain this ﬁnding. Other factors
(e.g. cost considerations) might have contributed to this result.
Limitations of the present analysis are primarily associated with
uncertainties of epidemiological estimates and the application of
study results to the entire patient population.
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OBJECTIVES: Real-world data on long-term dosing patterns
in ﬁrst time anti-TNFa inhibitor treated rheumatoid arthritis
patients is lacking. Such data are important for the calculation
of treatment cost, especially for products where the label
allows for varying doses and frequency of administrations.
METHODS: The Dutch Rheumatoid Arthritis Monitoring
(DREAM) project is a longitudinal, multi-centre patient register
monitoring biologic DMARD usage in clinical practice since
February 2003. Patients meeting the Dutch reimbursement
criteria (DAS28 > 3.2, inadequate response to 2 DMARDs
including methotrexate, no prior bDMARDs) were assessed at
three-month intervals for 48 months. Dosing was determined by
the attending rheumatologist guided by the recommended
labelled doses (adalimumab 40 mg every other week, etanercept
25 mg twice weekly, inﬂiximab 3 mg/kg at week 0, 2, 4, 8 and
every 8 weeks thereafter). Mean dose was calculated based on
the actual dose prescribed at each visit and the change over time
evaluated for each anti-TNFa. RESULTS: The mean baseline
doses for adalimumab (N = 374), etanercept (N = 432) and
inﬂiximab (N = 325) were 39.9 mg/two weeks, 24.2 mg twice
weekly, and 3.4 mg/kg per eight weeks. Mean baseline DAS28
and HAQ ranged from 5.2–5.4 and 1.3–1.4, respectively.
Nearly one-third of inﬂiximab patients were prescribed greater
than the labelled dose at baseline (32%, N = 105) compared to
2.5% and 0.2% for adalimumab and etanercept. At 12, 24, and
48 months follow-up, mean doses were: adalimumab, 41.5,
43.3, and 45.7 mg/two weeks (42 months); etanercept, 24.0,
24.9, and 23.9 mg twice per week (45 months); inﬂiximab, 4.3,
4.9, and 4.9 mg/kg/every eight weeks (48 months). Mean doses
in inﬂiximab patients prescribed greater than the recommended
labelled dose at baseline were 4.7, 5.2, and 5.6 mg/kg at the
same follow-up intervals. CONCLUSIONS: Longitudinal
patient registry data from The Netherlands show a marked and
continued dose escalation in RA patients prescribed inﬂiximab
as a ﬁrst-line anti-TNFa when compared to either adalimumab
or etanercept.
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OBJECTIVES: To determine the co-morbidity and direct cost
inﬂuence in patients with osteoporosis in a Spanish population
setting in under usual medical practice. METHODS: We per-
formed a transversal retrospective study realized beginning from
registers of subjects older than 44 years appertaining to seven
centers of primary care (year 2,006). A control group without
osteoporosis was formed. Main measures: general (age, gender),
general co-morbidities and speciﬁc (ICPC-2), Charlson index
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